Real-world utility of an amplicon-based next-generation sequencing liquid biopsy for broad molecular profiling in patients with advanced non–small-cell lung cancer
J Remon, L Lacroix, C Jovelet, C Caramella… - JCO precision …, 2019 - ascopubs.org
PURPOSE To assess the feasibility and utility of circulating tumor DNA (ctDNA) by amplicon-
based next-generation sequencing (NGS) analysis in the daily clinical setting in a cohort of …
based next-generation sequencing (NGS) analysis in the daily clinical setting in a cohort of …
[HTML][HTML] The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer
S Laufer-Geva, AB Rozenblum, T Twito… - Journal of Thoracic …, 2018 - Elsevier
Introduction Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA)
enables noninvasive genomic analysis of NSCLC patients. Although plasma-detected …
enables noninvasive genomic analysis of NSCLC patients. Although plasma-detected …
Impact of a clinical genomics program on trial accrual for targeted treatments: Practical approach overcoming barriers to accrual for underserved patients
CJ Farhangfar, GT Scarola, VA Morris… - JCO Clinical Cancer …, 2022 - ascopubs.org
PURPOSE Clinical trials of novel and targeted agents increasingly require biomarkers for
eligibility. Precision oncology continues to evolve, but challenges hamper broad use of …
eligibility. Precision oncology continues to evolve, but challenges hamper broad use of …
Peptide-affinity precipitation of extracellular vesicles and cell-free DNA improves sequencing performance for the detection of pathogenic mutations in lung cancer …
C Taylor, S Chacko, M Davey, J Lacroix… - International Journal of …, 2020 - mdpi.com
Liquid biopsy is a minimally-invasive diagnostic method that may improve access to
molecular profiling for non-small cell lung cancer (NSCLC) patients. Although cell-free DNA …
molecular profiling for non-small cell lung cancer (NSCLC) patients. Although cell-free DNA …
Pyramidal decision support framework leverages subspecialty expertise across enterprise to achieve superior cancer outcomes and personalized, precision care …
LD Bosserman, I Mambetsariev, C Ladbury… - Journal of Clinical …, 2022 - mdpi.com
The complexity of cancer care requires integrated and continuous support to deliver
appropriate care. An expert network with complementary expertise and the capability of …
appropriate care. An expert network with complementary expertise and the capability of …
Real-world clinical outcomes after genomic profiling of circulating tumor DNA in patients with previously treated advanced non-small cell lung cancer
S Olsen, J Liao, H Hayashi - Current Oncology, 2022 - mdpi.com
Comprehensive genomic profiling for advanced non-small cell lung cancer (NSCLC) can
identify patients for molecularly targeted therapies that improve clinical outcomes. We …
identify patients for molecularly targeted therapies that improve clinical outcomes. We …
Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer
N Wu, W Ge, RGW Quek, M Gleeson, JF Pouliot… - Future …, 2022 - Taylor & Francis
Background: Trends/outcomes associated with National Comprehensive Cancer Network
(NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer …
(NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer …
Liquid biopsies using circulating tumor DNA in non-small cell lung cancer
The development of targeted therapies has substantially improved outcomes for a subset of
patients with non-small cell lung cancer (NSCLC). 1 As treatments become more effective …
patients with non-small cell lung cancer (NSCLC). 1 As treatments become more effective …
[HTML][HTML] Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists
DM Waterhouse, WY Tseng, JL Espirito, NJ Robert - Clinical Lung Cancer, 2021 - Elsevier
Introduction Although guidelines recommend testing for actionable biomarkers for patients
with advanced or metastatic non–small cell lung cancer (NSCLC), testing rates have varied …
with advanced or metastatic non–small cell lung cancer (NSCLC), testing rates have varied …
[HTML][HTML] Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®
T White, S Szelinger, J LoBello, A King, J Aldrich… - Oncotarget, 2021 - ncbi.nlm.nih.gov
We developed and analytically validated a comprehensive genomic profiling (CGP) assay,
GEM ExTra, for patients with advanced solid tumors that uses Next Generation Sequencing …
GEM ExTra, for patients with advanced solid tumors that uses Next Generation Sequencing …